Business Insider

Axonics Modulation Technologies (AXNX) was downgraded to a Hold Rating at Wolfe Research

Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.
Business Insider

Axonics Modulation Technologies (AXNX) Receives a Hold from RBC Capital

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...
Nasdaq

Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

The market expects Axonics Modulation Technologies (AXNX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This ...
FierceBiotech

FTC asks Boston Scientific, Axonics for more info on their $3.7B deal, pushing back acquisition timeline

The Federal Trade Commission (FTC) is taking a closer look at Boston Scientific’s $3.7 billion proposal to acquire neuromodulation developer Axonics, a move that could push back the closing of the ...
Business Wire

Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, ...